*.*.228.27
药智数据企业版
量身打造,体验升级
立即前往
VIP试用申请
登录 注册
当前位置: 首页 > 药物分子靶点 反馈纠错 帮助中心
药智数据企业版注册数据库:增设了"联合申报"、"临床试验默认许可日期"等搜索条件,让搜索页面纬度更加全面,还有热点搜索和高级条件组合检索等检索功能 等你来体验!

一个药物有多个靶点,靶点与靶点采用分号隔开


药智数据官方招聘【创新药信息总监】点击查看职位详情


导出数据
药物名称 分子靶点 ATC编码 适应症
Esmolol Beta-1 adrenergic receptor C07AB09 For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.
Spaglumic acid Calcitonin receptor R01AC05 Used in patients with allergic conjunctivitis.
Ponatinib C-X-C chemokine receptor type 4 L01XE24 Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
Basiliximab Inositol phosphorylceramide synthase L04AC02 For prophylactic treatment of kidney transplant rejection
Adapalene Retinoic acid receptor gamma;Retinoic acid receptor beta;Retinoic acid receptor RXR-gamma;Retinoic acid receptor RXR-beta;Retinoic acid receptor alpha;Retinoic acid receptor RXR-alpha;Prostaglandin G/H synthase 2 D10AD03 For the topical treatment of comedo, papular and pustular acne (acne vulgaris) of the face, chest or back.
Sparfloxacin Calcitonin receptor J01MA09 For the treatment of adults with the following infections caused by susceptible strains microorganisms: community-acquired pneumonia (caused by Chlamydia pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, or Streptococcus pneumoniae) and acute bacterial exacerbations of chronic bronchitis (caused by Chlamydia pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, or Streptococcus pneumoniae).
Sulfadimethoxine Cyclin-dependent kinase 2 J01ED01 For use in the treatment of infections.
Naratriptan Dihydroorotate dehydrogenase (quinone), mitochondrial N02CC02 For the acute treatment of migraine attacks with or without aura in adults.
Afatinib Epidermal growth factor receptor;Receptor tyrosine-protein kinase erbB-2;Receptor tyrosine-protein kinase erbB-4 L01XE13 Afatinib is a kinase inhibitor indicated as monotherapy [3] for the first-line [Label] treatment of (a) Epidermal Growth Factor Receptor (EGFR) TKI (tyrosine kinase inhibitor)-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant EGFR mutations as detected by an FDA-approved test [Label], and (b) adult patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy [Label]. Recently, as of January 2018, the US FDA approved a supplemental New Drug Application for Boehringer Ingelheim's Gilotrif (afatinib) for the first line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test [4]. The new label includes data on three additional EGFR mutations: L861Q, G719X and S768I [4].
Ornithine Ornithine aminotransferase, mitochondrial;Ornithine carbamoyltransferase, mitochondrial;Arginase-1;Ornithine decarboxylase antizyme 1;Low affinity cationic amino acid transporter 2;Mitochondrial ornithine transporter 2;Cationic amino acid transporter 4;Hi A05BA06 Used for nutritional supplementation, also for treating dietary shortage or imbalance. It has been claimed that ornithine improves athletic performance, has anabolic effects, has wound-healing effects, and is immuno-enhancing.
Esomeprazole Potassium-transporting ATPase alpha chain 1 A02BD06 For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
Dextroamphetamine Synaptic vesicular amine transporter;Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter;Trace amine-associated receptor 1;Alpha-1A adrenergic receptor;Alpha-1B adrenergic receptor N06BA02 Used to treat attention deficit hyperactivity disorder (ADHD).
Paraldehyde Chymotrypsin-like elastase family member 1 N05CC05 Paraldehyde was used historically as a sedative and hypnotic [1]. It has been used in the treatment of seizures as an anticonvulsant [2].
Porfimer sodium C-X-C chemokine receptor type 4 L01XD01 Indicated in the treatment of esophageal cancer.
Sulfadoxine Cyclin-dependent kinase 2 G01AE10 Sulfadoxine is used in combination with pyrimethamine for the treatment or prevention of malaria. It can also be used to treat various infections in livestock as well. Sulfadoxine and pyrimethamine is indicated for the treatment of Plasmodium falciparum malaria in those patients in whom chloroquine resistance is suspected.
Cyclophosphamide DNA;Nuclear receptor subfamily 1 group I member 2 L01AA01 Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
Ipratropium Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3 R03BB01 For maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Pantoprazole Potassium-transporting ATPase alpha chain 1 A02BD04 Pantoprazole Injection: Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis Pantoprazole for injection is indicated for short-term treatment (7-10 days) of patients having gastroesophageal reflux disease (GERD) with a history of erosive esophagitis, as an alternative to oral medication in patients who are unable to continue taking pantoprazole delayed-release tablets. Safety and efficacy of pantoprazole injection as the initial treatment of patients having GERD with a history of erosive esophagitis have not been demonstrated at this time [Label]. Pathological Hypersecretion Associated with Zollinger-Ellison Syndrome Pantoprazole for injection is indicated for the treatment of pathological hypersecretory conditions associated with Zollinger-Ellison Syndrome or other neoplastic conditions [Label]. Pantoprazole Extended-Release Tablets/Oral suspension: Short-Term Treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD) Indicated in adults and pediatric patients five years of age and above for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been determined [13]. Maintenance of healing of erosive esophagitis Indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD [13]. Pathological hypersecretory conditions including Zollinger-Ellison syndrome Indicated for the long-term treatment of the above conditions [13].
Ciclopirox Sodium/potassium-transporting ATPase subunit alpha-1 D01AE14 Used as a topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum.
Phenformin Vanilloid receptor A10BA01 For the reatment of type II diabetes mellitus.